BIO Proposes Increased Imputed Base Rates for 2002 Medicare OPPS
This article was originally published in The Gray Sheet
Executive Summary
The Biotechnology Industry Organization (BIO) says it will seek a blended reimbursement rate of 80% of the average wholesale price (AWP) for drugs and biologics if the trade group is unable to delay the Centers for Medicare & Medicaid Services' 68.9% pro rata reduction in "pass-through" payments for new medical technologies
You may also be interested in...
Medicare OPPS Administrative Burden On CMS Is Of Concern To MedPAC
The Medicare Payment Advisory Commission's upcoming recommendation on the future of the hospital outpatient prospective payment system (OPPS) "pass-through" payments is likely to hinge on the panel's perception of the size of the administrative undertaking for the Center for Medicare & Medicaid Services in implementing the system
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.